GILD Forecast: Gilead Sciences Has Short Term Potential, But The Long Term Is Worrisome


This article was written by Grant Goldstein, a Financial Analyst at I Know First



  • GILD Q1 Misses Expectations
  • Gilead's Future Expenditures
  • Bearish GILD Recommendation
I Know First.  

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Bright Path Ahead for Gilead Sciences: Algorithmic Forecast

This article was written by Cole Winston, a Financial Analyst at I Know First.

 Bright Path Ahead for Gilead Sciences

  • Governance
  • Business and Financial Performance
  • Price Action: Ending Bearish Sentiment
  • Bullish Forecast for GILD

Tesla Stock PredictionRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

Gilead Stock Forecast: Can Pricing Pressure and Competition Stop Gilead’s 5-year Bull Run?

reuben 2Reuben Bor is a Financial Analyst Intern at I Know First
  • Gilead Sciences has returned over 330% to shareholders in the past 5 years
  • Merck has released a rival Hepatitis C drug that is substantially cheaper than Gilead’s Harvoni
  • Massachusetts’s Attorney General has threatened the company with legal action concerning the company’s pricing policies
  • Gilead Stock 2016 Outlook
GILD stock analysis

premiumRead The Full Premium Article

Subscribe to our exclusive content in the PREMIUM section

Gilead Sciences Stock Prediction: An Algorithmic Forecast (GILD)

I Know First published a bullish forecast on Gilead Sciences, an American biotech company, on Seeking Alpha. Having explained how I Know First’s algorithm works, it is worthwhile to see if the algorithm agrees with the bullish fundamental analysis of the company. The three-month and one-year forecasts for Gilead Sciences are included. Gilead Sciences Stock Prediction

Biotech Stocks Based On Neural Networks: Up to 130.61% Return in 3 Months

Package Name: Biotech Stocks
Forecast Length: 3 Months (5/15/15 – 8/15/15)
I Know First Average: 17.44%

Read The Full Forecast

Biotech Stocks Based On Neural Networks

GILD Stock News: Continue Buying At Current Prices


  • Gilead Sciences’ stock price has increased over 50% in the last year, in most part because of the rapid growth of its HCV drugs.gild stock news
  • Sales of these drugs will not fall off, with plenty of additional growth still to be had.
  • Along with the success in the HIV market and potential in the oncology field, the company’s pipeline is currently robust.
  • With a cheap valuation and a large cash pile with which to return value to shareholders, this stock is still attractive to long-term investors.
  • I Know First algorithm is bullish on Gilead Sciences over the next year, believing the stock price will climb to new highs.

Read The Full Article Here